Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones International Internet UCITS ETF 05.12.2025 FDNI.LN IE00BT9PVG14 400,002.00 USD 9,098,563.22 22.746 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 05.12.2025 UIGB IE00079WNSI6 16,334.00 GBP 388,199.72 23.766 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 05.12.2025 UNCU.LN IE00BD6GCF16 798,869.00 USD 32,793,569.09 41.050 ...
-
Integral AI Unveils World’s First AGI-capable Model
TOKYO--(BUSINESS WIRE)--Team led by ex-Googlers creates an interactive sandbox showcasing the world’s first AGI-capable model....
-
Babcock & Wilcox Enterprises Announces Full Redemption of Notes
AKRON, Ohio--(BUSINESS WIRE)--B&W has completed the previously announced redemption of all $26 million aggregate principal amount outstanding of our 8.125% Senior Notes due 2026....
-
Ingevity announces results of portfolio review, including plans to explore strategic alternatives for Advanced Polymer Technologies segment and Road Markings business
NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity today announced it has completed the company’s previously disclosed portfolio review process and is exploring potential divestitures...
-
Kallyope Announces Positive Results from Phase 2b Study of Elismetrep for the Acute Treatment of Migraine
NEW YORK--(BUSINESS WIRE)--Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for migraine and metabolism, today announced positive results from a Phase 2b study of the company’s lead candidate elismetrep, an oral Transient Receptor Potential Melastatin 8 (TRPM8) antagonist being studied for the acute treatment of migraine. In the study, elismetrep delivered a favorable clinical profile through its novel mechani...
-
Ingevity announces key leadership transitions
NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity today announced pivotal executive leadership changes as it completes its strategic portfolio review and positions the company for the future...
-
Natixis Syndicate UK Regulatory Announcement: Post-Stabilisation Announcement
LONDON--(BUSINESS WIRE)-- POST-STABILISATION ANNOUNCEMENT Date: 8th December 2025 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. PERNOD RICARD Post-stabilisation Period Announcement Further to the pre-stabilisation period announcement dated 28th October 2025, Natixis (contact: Christopher Agathangelou; telephone: 0158550814) hereby gives notice that no stabilisation (within the meaning of Article 3.2(...
-
Babcock & Wilcox Receives Limited Notice to Proceed to Supply CO2 Capture Technology for U.S. Power Plant
AKRON, Ohio--(BUSINESS WIRE)--B&W has received limited notice to proceed with engineering and long-lead procurement on a SolveBright™ post-combustion carbon-capture system....